secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2026-04-06T23:59:59+00:00
Accession:  0001193125-26-142885
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio prices $17.5M public offering of 12.5M shares and warrants; net proceeds ~$16M
--------------------------------------------------------------------------------

- 12.5M shares and Series A/B warrants (each exercisable for 1 share at $1.40) priced at $1.40 per unit.
- Gross proceeds $17.5M; net proceeds ~$16M after underwriting discounts and expenses.
- Underwriters granted 30-day option to buy up to 1.875M additional shares and warrants.
- Series A warrants expire in 1 year, Series B warrants in 5 years; beneficial ownership cap 4.99%.
- Closing expected April 6, 2026; Piper Sandler sole book-running manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/0001193125-26-142885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/d137120d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-142885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer